Total Participants |
554 (100%) |
MAP |
286 (51.6%) |
ROS |
268 (48.4%) |
Demographic |
|
Age at Death (years) |
90.4 (6.0) |
Female |
395 (71.3%) |
Education (years) |
15.8 (3.6) |
White, Non-Hispanic |
536 (96.9%) |
Clinical Diagnosis |
|
Cognitive Impairment at Baseline |
|
Mild Cognitive Impairment (MCI) |
151 (27.3%) |
Alzheimer’s Disease (AD) |
33 (6.0%) |
Cognitive Impairment at Death |
|
Mild Cognitive Impairment (MCI) |
143 (26.3%) |
Alzheimer’s Disease (AD) |
230 (42.4%) |
Cognitive |
|
Number of Annual Cognitive Evaluations |
9.3 (4.6) |
Baseline MMSE (score out of 30) |
27.7 (2.8) |
Proximate to Death MMSE |
20.5 (9.2) |
Global Cognition, Baseline (composite of 17 z-scores) |
−0.07 (0.59) |
Global Cognition, Proximate to Death |
−0.85 (1.11) |
Global Cognition, Estimated Linear Rate of Change (per year) |
−0.10 (0.10) |
Pathologic |
|
Postmortem Interval (hours) |
8.7 (5.8) |
Amyloid Load (square root transform) |
2.04 (1.19) |
Tangles (square root transform) |
2.28 (2.12) |
Gross Infarcts (present) |
189 (34.1%) |
Lewy Bodies (present) |
127 (22.9%) |
Hippocampal sclerosis (present) |
67 (12.1%) |
TDP-43 (stage 0-3) |
1.11 (1.13) |
Cerebral amyloid angiopathy (semiquantitative 0-3) |
1.13 (1.05) |
Atherosclerosis (semiquantitative 0-3) |
1.11 (0.84) |
Arteriolosclerosis (semiquantitative 0-3) |
1.03 (0.86) |